ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220

Tuesday, August 5, 2014

Submitted by

Mark Ferguson

Source

Source Name: Annals of Thoracic Surgery

Source URL: http://www.annalsthoracicsurgery.org/article/S0003-4975%2814%2901052-2/abstract

Author(s)

Kemp H. Kernstine, James Moon, Michael J. Kraut, Katherine M.W. Pisters, Joshua R. Sonett, Valerie W. Rusch, Charles R. Thomas, Thomas K. Waddell, James R. Jett, Alan P. Lyss, Steven M. Keller, David R. Gandara

Optimal management of superior sulcus tumors remains challenging. This SWOG protocol was a feasibility study of the utility of consolidation therapy with docetaxel in addition to cisplatin-etoposide, 45Gy, and possible resection. Of 46 registered pts, 86% completed induction therapy, 66% underwent resection, and 45% completed consolidation therapy. The R0 resection rate in surgical pts was 97%, and the complete or near-complete pathologic response rate in resected patients was 72%. Overall 3-year survival was 61%.